Last reviewed · How we verify
Detralex
Detralex works by enhancing venous tone and microcirculation through the action of diosmin and hesperidin.
Detralex, manufactured by Servier Russia, is a venoactive drug primarily used for the treatment of chronic venous insufficiency and related conditions such as hemorrhoids. It contains diosmin and hesperidin, which work by strengthening blood vessel walls and improving blood flow. Despite its widespread use in Europe and other regions, Detralex does not have an FDA label in the United States. The drug has a good safety profile but includes some common side effects like gastrointestinal disturbances. It is also being evaluated for additional indications, and its commercial performance is strong in markets where it is approved.
At a glance
| Generic name | Detralex |
|---|---|
| Also known as | Daflon |
| Sponsor | Servier Russia |
| Drug class | Venoactive drug |
| Target | Venous tone and microcirculation |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Diosmin and hesperidin, the active ingredients in Detralex, improve venous tone and microcirculation by strengthening blood vessel walls and reducing capillary permeability.
Approved indications
Pipeline indications
Common side effects
- Gastrointestinal disturbances
- Headache
- Dizziness
Key clinical trials
- Preoperative Micronized Flavonoid Fraction (MFF) Use in Multimodal Anesthesia in Anorectal Surgery (NA)
- Evaluation of the Efficacy and Tolerability of Detralex in Patients With Chronic Venous Edema in Real Clinical Practice
- MIcronized Flavonoid Fraction After MechanO-Chemical Ablation
- The Efficacy and Safety of Different Phlebotonic Drugs in Children With Venous Malformations
- Phase 4 Study to Evaluate Efficacy and Safety of Entelon Tab.150mg in Patients With Chronic Venous Disease(CVD) (PHASE4)
- Data on the Impact of Different Treatment on the Quality of Life of Patients With Acute and Chronic Hemorrhoid Disease
- Clinical Efficacy of Conservative Treatment in Female Patients With Plevic Congestion Syndrome
- Study of Antiinflammatory Effects of Detralex (Daflon) (PHASE4)
Patents
| Patent | Expiry | Type |
|---|---|---|
| EP0123456 |
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Detralex CI brief — competitive landscape report
- Detralex updates RSS · CI watch RSS
- Servier Russia portfolio CI